Gemma Dickinson

Gemma Dickinson

UNVERIFIED PROFILE

Are you Gemma Dickinson?   Register this Author

Register author
Gemma Dickinson

Gemma Dickinson

Publications by authors named "Gemma Dickinson"

Are you Gemma Dickinson?   Register this Author

15Publications

289Reads

10Profile Views

Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.

Clin Pharmacol Ther 2020 Jan 12;107(1):246-256. Epub 2019 Sep 12.

Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, Indiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1596DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925622PMC
January 2020

Living with Polyneuropathy Organomegaly Endocrinopathy Monoclonal gammopathy Skin changes (POEMS) syndrome: a case study of healthcare experiences and quality of life.

Disabil Rehabil 2019 Dec 14:1-9. Epub 2019 Dec 14.

The Department of Clinical Neuropsychology, Salford Royal NHS Foundation Trust, Northern Care Alliance, Salford, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09638288.2019.1700563DOI Listing
December 2019

Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease.

J Clin Pharmacol 2017 06 1;57(6):739-746. Epub 2017 Feb 1.

Eli Lilly and Company, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.865DOI Listing
June 2017

Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.

J Pharmacol Exp Ther 2016 Feb 1;356(2):260-6. Epub 2015 Dec 1.

PET Center, Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut (M.N., M.Z., S.H., N.N., S.L., J.R., Y.H., R.C.); Eli Lilly and Company, Indianapolis, Indiana (G.D., J.W., R.B., J.T.); ClinBAY, Belgium (F.V.); and Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (A.N., M.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.115.229278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727157PMC
February 2016

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.

Pharm Res 2015 Jun 2;32(6):1864-83. Epub 2014 Dec 2.

Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, The University of Manchester, Stopford Building, Room 3.32, Oxford Road, Manchester, M13 9PT, UK,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11095-014-1581-2
Publisher Site
http://dx.doi.org/10.1007/s11095-014-1581-2DOI Listing
June 2015

Evaluation of methods for achieving stable INR in healthy subjects during a multiple-dose warfarin study.

Eur J Clin Pharmacol 2012 Mar 1;68(3):239-47. Epub 2011 Sep 1.

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-011-1114-4DOI Listing
March 2012

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

J Clin Oncol 2009 Apr 23;27(10):1660-6. Epub 2009 Feb 23.

Christie Hospital National Health Service Foundation Trust, Clinical and Experimental Pharmacology, Paterson Institute for Cancer Research, and School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.5677DOI Listing
April 2009

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example.

Br J Clin Pharmacol 2007 Jul 12;64(1):14-26. Epub 2007 Feb 12.

Academic Unit of Clinical Pharmacology, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2007.02850.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000610PMC
July 2007

Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application.

J Clin Pharmacol 2007 Feb;47(2):175-86

Academic Unit of Clinical Pharmacology, School of Medicine, University of Sheffield, M-floor, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0091270006294279DOI Listing
February 2007